Pomerantz Law Firm Launches Investigation into ADMA Biologics Following Serious Allegations of Securities Fraud
Pomerantz Law Firm Investigates ADMA Biologics
The Pomerantz Law Firm has taken proactive steps to investigate claims made on behalf of the investors of ADMA Biologics, Inc., trading under the ticker ADMA on NASDAQ. This investigation comes in light of a report released by Culper Research, which raised serious allegations regarding the company's business practices and financial reporting.
Background of the Investigation
On March 24, 2026, Culper Research published a critical short report about ADMA, contending that the company’s reported growth figures were largely inflated due to alleged deceptive practices, including a method they referred to as
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.